Please ensure Javascript is enabled for purposes of website accessibility

Why TransEnterix Stock Soared Today

By Keith Speights - Jul 10, 2019 at 4:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors cheered the surgical robot maker's sale of assets and the added cash the divestiture will bring.

What happened

Shares of TransEnterix (ASXC 2.74%) were soaring 25.2% as of 3:15 p.m. EDT on Wednesday. The big gain came after the maker of robotic surgical systems announced that it was selling some of its AutoLap image-based laparascopic positioning system assets to Great Belief International Ltd. (GBIL) for $47 million.

So what

The key news with TransEnterix's divestiture is the cash that it will generate. The stock tanked in the first half of 2019 as the company continued to hemorrhage cash. At the end of the first quarter, TransEnterix only had $49 million in restricted cash and short-term investments. Although the company said that amount combined with its debt financing was enough to fund operations through late 2020, investors have been understandably concerned that more shareholder dilution could be on the way.

Businessman holding a lot of cash in his hands

Image source: Getty Images.

TransEnterix's deal with GBIL includes a $5 million cash payment by July 31. This payment will be followed by another $12 million in cash by Nov. 30, 2019. GBIL will also invest $30 million in TransEnterix no later than Sept. 30, 2019, at a price of $2 per share. That's a great price tag considering that TransEnterix's share price is well below $2 even after today's big jump.

AutoLap wasn't a core asset for TransEnterix, so investors really liked the move to sell it. TransEnterix acquired it with its acquisition last year of the assets of Medical Surgical Technologies.

Now what

This divestiture is only a temporary boon. The real key for the company's success is for sales to pick up for its Senhance robotic surgical system. CEO Todd Pope stated in May that the company expects "to show meaningful revenue growth in the second half of the year." Investors will want to watch its upcoming quarterly updates to see if the company can deliver on its expectations.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Asensus Surgical, Inc. Stock Quote
Asensus Surgical, Inc.
ASXC
$0.42 (2.74%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.